DUBLIN–(BUSINESS WIRE)–The report “Global Non-Invasive Cancer Diagnostics Market Research and Forecast 2022-2028” has been added to from ResearchAndMarkets.com offer.

Global non-invasive cancer diagnostics market expected to grow at a CAGR of 7.2%

A non-invasive cancer diagnosis is a method of detecting cancerous conditions with just a small incision in the body. Rise in chronic cancers and growing demand for minimally invasive diagnostics is driving the non-invasive cancer diagnostics market across the globe. According to the WHO, approximately 10 million deaths occurred from cancer in 2020.

The most common new cancer cases in 2020 include breast cancer (2.26 million), lung cancer (2.21 million), colon and rectal cancer (1.93 million), cancer of the prostate (1.41 million), stomach cancer (1.09 million) and others. This large number of cancer cases has shifted global attention towards the adoption of early cancer detection and diagnosis techniques.

Additionally, growing awareness programs, rising healthcare expenditures, and initiatives by governments and healthcare organizations are driving the market growth across the globe. Cancer Research UK, the Department of Health, NHS England and Public Health England, in collaboration, launched the National Awareness and Early Diagnosis Initiative (NAEDI) in 2007.

The initiative aims to raise awareness of cancer among the public and healthcare professionals, as well as to encourage early detection. A growing number of such initiatives are educating patients around the world about cancer diagnosis and treatment. However, high cost of treatment and stringent regulatory guidelines are the factors that are hindering the growth of the non-invasive cancer diagnostics market over the forecast period.

Sector outlook

Due to the rapid increase in the number of breast cancer cases globally, breast cancer accounted for one of the largest non-invasive cancer diagnostic market shares in 2020. Based on the techniques, the market is segmented into clinical chemistry,

The breast cancer segment is expected to hold a major share of the global non-invasive cancer diagnostics market

Among the techniques in the non-invasive cancer diagnostics market, the breast cancer segment held the highest share in 2020 and is also expected to grow during the forecast period. Rising number of breast cancers in the world is driving the growth of the market. For example, according to the World Health Organization, in 2020 an estimated 2.3 million women were diagnosed with breast cancer and 685,000 died worldwide.

Regional outlook

North America is predicted to dominate the global non-invasive cancer diagnostics market due to well-established healthcare infrastructure, technology development, government support and high prevalence of such cancer cases among the people.

Asia-Pacific Expected to Witness Huge Growth in Global Non-invasive Cancer Diagnostics Market

Asia-Pacific is expected to witness considerable growth in the global non-invasive cancer diagnostics market. Rising prevalence of cancer patients and growing awareness of minimally invasive diagnostic equipment are the major factors driving the market growth over the forecast period.

Market Player Perspectives

Major players in the non-invasive cancer diagnostics market include A&G Pharmaceutical Inc., BioVie Inc., Laboratory Corporation of America, LungLife AI, Inc., Novartis AG, GE Healthcare, AVIVA Biosciences Corp., Quest Diagnostics Inc. and others. .

Market players are significantly contributing to the growth of the market by adopting various strategies including mergers and acquisitions, collaborations, financing, and new product launches to stay competitive in the market.

The report covers

  • Market value data analysis of 2020 and forecast till 2027.

  • Annualized market revenue ($millions) for each market segment.

  • Country analysis of major geographic regions.

  • Key companies operating in the global non-invasive cancer diagnostics market. Based on data availability, information related to new product launches and relevant news is also available in the report.

  • Analysis of business strategies by identifying key market segments positioned for strong growth in the future.

  • Analysis of market entry and expansion strategies.

  • Competitive strategies by identifying “who stands where” in the market.

Companies cited

  • Agilent Technologies, Inc.

  • A&G Pharmaceutical, Inc.

  • Accelerate recovery from brain cancer

  • Admera Health

  • AVIVA Systems Biology Corp.

  • BioVie Inc.

  • Datar Care Genetics

  • Exosomal SPA

  • Flatiron Health, Inc.

  • General Electricity Company.

  • IV Diagnostics, Inc.

  • Laboratory Society of America

  • LungLife AI, Inc. (Cynvenio Biosystems)

  • NeoGenomics Laboratories, Inc.

  • Novartis AG

  • Novcure GmbH

  • Novigenix AG

  • QIAGEN GmbH

  • Quanterix Corp.

  • Quest Diagnostics Inc.

  • Thermo Fisher Scientific Inc. (Affymetrix Inc.)

For more information about this report visit https://www.researchandmarkets.com/r/4j1yuo

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.

Source link

Leave A Reply